CONTEXT: Thyroid cancer is a major component of Cowden syndrome (CS). CS patients with an underlying PTEN mutation (PTEN(mut+)) have a 70-fold increased risk of developing epithelial thyroid cancer. In contrast, less than 1% of sporadic epithelial thyroid cancer patients carry a germline PTEN mutation. Cost-efficient markers capable of shortlisting thyroid cancers for CS genetic testing would be clinically useful. OBJECTIVE: Our objective was to analyze the utility of patient blood phosphate and tensin homolog deleted on chromosome 10 (PTEN) protein levels in predicting germline PTEN mutations. DESIGN, SETTING, AND PATIENTS: We conducted a 5-yr, multicenter prospective study of 2792 CS and CS-like patients, all of whom had comprehensive PTEN analysis. Analysis of PTEN and downstream proteins by immunoblotting was performed on total protein lysates from patient-derived lymphoblast lines. We compared blood PTEN protein levels between PTEN(mut+) patients and those with variants of unknown significance or wild-type PTEN (PTEN(wt/vus)). MAIN OUTCOME MEASURES: We assessed the utility of PTEN protein levels in predicting germline PTEN mutations. RESULTS: Of 2792 CS/CS-like patients, 721 patients had thyroid cancer; 582 of them (81%) had blood PTEN protein analyzed. PTEN germline pathogenic mutations were present in 27 of 582 patients (4.6%). Ninety-six percent (26 of 27) of PTEN(mut+) patients had blood PTEN protein levels in the lowest quartile as compared with 25% (139 of 555) of PTEN(wt/vus) patients (P < 0.001). Low blood PTEN levels predicted for PTEN(mut+) cases with a 99.76% negative predictive value (95% confidence interval = 98.67-99.96) and a positive test likelihood ratio of 3.84 (95% confidence interval = 3.27-4.52). CONCLUSIONS: Our study shows that low blood PTEN protein expression could serve as a screening molecular correlate to predict for germline PTEN mutation in CS and CS-like presentations of thyroid cancer.
CONTEXT: Thyroid cancer is a major component of Cowden syndrome (CS). CS patients with an underlying PTEN mutation (PTEN(mut+)) have a 70-fold increased risk of developing epithelial thyroid cancer. In contrast, less than 1% of sporadic epithelial thyroid cancerpatients carry a germline PTEN mutation. Cost-efficient markers capable of shortlisting thyroid cancers for CS genetic testing would be clinically useful. OBJECTIVE: Our objective was to analyze the utility of patient blood phosphate and tensin homolog deleted on chromosome 10 (PTEN) protein levels in predicting germline PTEN mutations. DESIGN, SETTING, AND PATIENTS: We conducted a 5-yr, multicenter prospective study of 2792 CS and CS-like patients, all of whom had comprehensive PTEN analysis. Analysis of PTEN and downstream proteins by immunoblotting was performed on total protein lysates from patient-derived lymphoblast lines. We compared blood PTEN protein levels between PTEN(mut+) patients and those with variants of unknown significance or wild-type PTEN (PTEN(wt/vus)). MAIN OUTCOME MEASURES: We assessed the utility of PTEN protein levels in predicting germline PTEN mutations. RESULTS: Of 2792 CS/CS-like patients, 721 patients had thyroid cancer; 582 of them (81%) had blood PTEN protein analyzed. PTEN germline pathogenic mutations were present in 27 of 582 patients (4.6%). Ninety-six percent (26 of 27) of PTEN(mut+) patients had blood PTEN protein levels in the lowest quartile as compared with 25% (139 of 555) of PTEN(wt/vus) patients (P < 0.001). Low blood PTEN levels predicted for PTEN(mut+) cases with a 99.76% negative predictive value (95% confidence interval = 98.67-99.96) and a positive test likelihood ratio of 3.84 (95% confidence interval = 3.27-4.52). CONCLUSIONS: Our study shows that low blood PTEN protein expression could serve as a screening molecular correlate to predict for germline PTEN mutation in CS and CS-like presentations of thyroid cancer.
Authors: P L Dahia; R C Aguiar; J Alberta; J B Kum; S Caron; H Sill; D J Marsh; J Ritz; A Freedman; C Stiles; C Eng Journal: Hum Mol Genet Date: 1999-02 Impact factor: 6.150
Authors: D J Marsh; J B Kum; K L Lunetta; M J Bennett; R J Gorlin; S F Ahmed; J Bodurtha; C Crowe; M A Curtis; M Dasouki; T Dunn; H Feit; M T Geraghty; J M Graham; S V Hodgson; A Hunter; B R Korf; D Manchester; S Miesfeldt; V A Murday; K L Nathanson; M Parisi; B Pober; C Romano; C Eng Journal: Hum Mol Genet Date: 1999-08 Impact factor: 6.150
Authors: Carla Di Loreto; Gianluca Tell; Marta Pestrin; Maura Pandolfi; Giuseppe Damante; Fabio Puglisi Journal: Cancer Lett Date: 2004-11-23 Impact factor: 8.679
Authors: A Perren; L P Weng; A H Boag; U Ziebold; K Thakore; P L Dahia; P Komminoth; J A Lees; L M Mulligan; G L Mutter; C Eng Journal: Am J Pathol Date: 1999-10 Impact factor: 4.307
Authors: Joseph D Buxbaum; Guiqing Cai; Pauline Chaste; Gudrun Nygren; Juliet Goldsmith; Jennifer Reichert; Henrik Anckarsäter; Maria Rastam; Christopher J Smith; Jeremy M Silverman; Eric Hollander; Marion Leboyer; Christopher Gillberg; Alain Verloes; Catalina Betancur Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2007-06-05 Impact factor: 3.568
Authors: Rosemary E Teresi; Kevin M Zbuk; Marcus G Pezzolesi; Kristin A Waite; Charis Eng Journal: Am J Hum Genet Date: 2007-08-15 Impact factor: 11.025
Authors: Scott K Sherman; Jessica E Maxwell; Qining Qian; Andrew M Bellizzi; Terry A Braun; Mark D Iannettoni; Benjamin W Darbro; James R Howe Journal: Cancer Genet Date: 2014-11-15
Authors: Haider Mahdi; Jessica L Mester; Emily A Nizialek; Joanne Ngeow; Chad Michener; Charis Eng Journal: Cancer Date: 2014-11-05 Impact factor: 6.860